GANX vs. AADI, NBRV, CKPT, RMTI, EQ, BOLT, IMRX, HCWB, EGRX, and BLRX
Should you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Checkpoint Therapeutics (CKPT), Rockwell Medical (RMTI), Equillium (EQ), Bolt Biotherapeutics (BOLT), Immuneering (IMRX), HCW Biologics (HCWB), Eagle Pharmaceuticals (EGRX), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical preparations" industry.
Gain Therapeutics (NASDAQ:GANX) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.
Gain Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -270.04%. Aadi Bioscience's return on equity of -52.53% beat Gain Therapeutics' return on equity.
In the previous week, Aadi Bioscience had 6 more articles in the media than Gain Therapeutics. MarketBeat recorded 6 mentions for Aadi Bioscience and 0 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.48 beat Aadi Bioscience's score of 0.06 indicating that Gain Therapeutics is being referred to more favorably in the media.
Gain Therapeutics received 11 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 61.11% of users gave Gain Therapeutics an outperform vote while only 50.00% of users gave Aadi Bioscience an outperform vote.
12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 11.0% of Gain Therapeutics shares are owned by insiders. Comparatively, 35.8% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Gain Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
Gain Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 217.16%. Aadi Bioscience has a consensus target price of $24.67, suggesting a potential upside of 1,240.58%. Given Aadi Bioscience's higher probable upside, analysts plainly believe Aadi Bioscience is more favorable than Gain Therapeutics.
Gain Therapeutics has higher earnings, but lower revenue than Aadi Bioscience. Gain Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Gain Therapeutics and Aadi Bioscience tied by winning 9 of the 18 factors compared between the two stocks.
Get Gain Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gain Therapeutics Competitors List
Related Companies and Tools
